Predilife (XPAR:ALPRE) Debt-to-Equity : -7.78 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Predilife Debt-to-Equity?

Predilife's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.69 Mil. Predilife's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €6.80 Mil. Predilife's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €-0.96 Mil. Predilife's debt to equity for the quarter that ended in Jun. 2023 was -7.78.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Predilife's Debt-to-Equity or its related term are showing as below:

XPAR:ALPRE' s Debt-to-Equity Range Over the Past 10 Years
Min: -128.92 Med: -1.62 Max: 186.88
Current: -7.78

During the past 7 years, the highest Debt-to-Equity Ratio of Predilife was 186.88. The lowest was -128.92. And the median was -1.62.

XPAR:ALPRE's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.22 vs XPAR:ALPRE: -7.78

Predilife Debt-to-Equity Historical Data

The historical data trend for Predilife's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predilife Debt-to-Equity Chart

Predilife Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

-128.92

-1.95

3.79

-3.50

-1.40

Predilife Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity	Get a 7-Day Free Trial									-4.64	-3.50	-1.49	-1.40	-7.78

Competitive Comparison of Predilife's Debt-to-Equity

For the Diagnostics & Research subindustry, Predilife's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Predilife's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Predilife's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Predilife's Debt-to-Equity falls into.

Predilife Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Predilife's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.653	+	6.635)	/	-5.22
	=	-1.40

Predilife's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.694	+	6.796)	/	-0.963
	=	-7.78

Predilife (XPAR:ALPRE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Predilife Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Predilife's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Predilife (XPAR:ALPRE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Predilife SA (XPAR:ALPRE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

114 rue Edouard Vaillant Espace Maurice Tubiana, Villejuif, Paris, FRA, 94800

Website

https://www.predilife.com

Predilife SA develops solutions of predictive medicine combining proven medical techniques (genetic tests, medical imaging) and mathematical models using a large number of statistical data that could allow each individual to define his risk profile for the occurrence of a large number of serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.

Predilife (XPAR:ALPRE) Headlines

No Headlines